EVENT DETAILS
Thursday, November 29, 2018
Sheraton Springfield Monarch Place Hotel
1 Monarch Place,
Springfield, MA 01144
Time
8:00 AM - 5:00 PM
Total Credits
7 Contact Hour(s)
Target Audience
Nurse , Pharmacist , Pharmacy Technician
Cost
$129.00
Registration closes on 11/28/2018 at 11:00 PM
 

Registration will be held from 8:00 am - 8:30 am. Continental breakfast will be served during this time.

A plated lunch will be served from 12:00 pm - 1:00 pm.

Refreshments will be served during the afternoon programs.

 

AGENDA

Scheduled CE Activities Thursday, November 29, 2018
  
Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and mortality, and is now the third leading cause of death in the United States. An estimated 12.7 million Americans have been diagnosed with COPD, but approximately 24 million adults have evidence of impaired lung function. In 2010, the total national medical costs attributable to COPD were estimated at $32.1 billion dollars annually and are projected to exceed $49 billion by 2020. Despite its prevalence and significant cost burden, opportunities for optimal medical management are often missed. Daily long-acting bronchodilators are recommended as first-line treatment in most cases of COPD, but less than 60% of eligible patients actually receive a prescription for these agents.
 
 
Pharmacist Learning Objectives
  • Identify the pathogenesis, associated risk factors, and clinical presentation of COPD
  • List the evidence-based strategies published in the 2018 GOLD Report to help guide therapeutic decision making
  • Recognize the safety, efficacy and clinical rationale of utilizing dual bronchodilator therapy in the management of COPD
  • Identify interventions shown to improve health status and reduce future exacerbations
  • Recognize the proper use of various inhalation devices to support patient self-management education
Pharmacy Technician Learning Objectives
  • Identify the risk factors and presentation of COPD
  • Recognize the role of dual bronchodilator therapy in the management of COPD
  • Identify patient communications that warrant referral to the pharmacist for evaluation of further intervention options in the management of COPD
  • Recognize delivery devices that may require additional patient education and/or referral to the pharmacist for proper delivery technique
Nurse Learning Objectives
  • Identify the pathogenesis, associated risk factors, and clinical presentation of COPD.
  • List the evidence-based strategies published in the 2018 GOLD Report to help guide therapeutic decision making.
  • Recognize the safety, efficacy and clinical rationale of utilizing dual bronchodilator therapy in the management of COPD
  • Identify interventions shown to improve health status and reduce future exacerbations
  • Recognize the proper use of various inhalation devices to support patient self-management education
 
Faculty
Timothy HuddBS, PharmD, RPh, AE-C
Associate Professor of Pharmacy Practice, Massachusetts College of Pharmacy & Health Sciences
 
ACPE UAN
0280-0000-18-096-L01-P (Knowledge-Based)
0280-0000-18-096-L01-T (Knowledge-Based)
0280-0000-18-096-L01-N (Knowledge-Based)
 
Credits
1.5
 
Handouts
 
Supported By
American Health Resources
 
 
 
Pharmacist Learning Objectives
  • Identify the role of guideline-directed medical therapy in reducing hospitalization for patients with chronic heart failure, including the role of newer agents
  • Indicate clinical services that improve patient care and their role in transitions of care
  • Using patient scenarios, identify appropriate plans to optimize care for patients with chronic heart failure
Pharmacy Technician Learning Objectives
  • Identify newer agents for the treatment of chronic heart failure by both brand and generic name
  • Identify key opportunities for pharmacist referral in patients with chronic heart failure
Nurse Learning Objectives
  • Identify the role of guideline-directed medical therapy in reducing hospitalization for patients with chronic heart failure, including the role of newer agents
  • Indicate clinical services that improve patient care and their role in transitions of care
  • Using patient scenarios, identify appropriate plans to optimize care for patients with chronic heart failure
 
Faculty
Jason CrossPharmD, BCPS
Associate Professor of Pharmacy Practice, Massachusetts College of Pharmacy & Health Sciences
 
ACPE UAN
0280-0000-18-095-L01-P (Knowledge-Based)
0280-0000-18-095-L01-T (Knowledge-Based)
0280-0000-18-095-L01-N (Knowledge-Based)
 
Credits
1.5
 
Handouts
 
Supported By
BayHealth Medical Center
 
For nearly 30 years, HbA1c has been the accepted gold-standard measurement of diabetes outcomes. Patients and clinicians have relied on the 3-month average blood glucose to assess the efficacy of diabetes therapies and inform treatment decisions, and it has become the primary endpoint for most diabetes drug approval studies. But HbA1c alone should not be the only consideration based on newer evidence and other outcomes such as cardiovascular, renal, hypoglycemia, and changes in body weight should be considered when treating the patient.
 
 
Pharmacist Learning Objectives
  • Recognize key elements of the ADA and AACE guidelines and identify new evidence of pharmacotherapies that pertain to non-glycemic outcomes
  • Recognize treatment options that optimize outcomes beyond A1c such as hypoglycemia, weight as well as cardiovascular and renal outcomes in patients with type 2 diabetes
  • Identify appropriate elements of an evidence-based treatment regimen that optimizes outcomes beyond hemoglobin A1c in patients with type 2 diabetes
Pharmacy Technician Learning Objectives
  • Recognize key elements of the newest ADA and AACE guidelines within the context of identifying patients who may benefit from a referral for pharmacist consultation.
  • Recognize treatment options for type 2 diabetes by generic name and drug classification.
  • Identify common factors for patients with type 2 diabetes that warrant referral to the pharmacist for consultation.
Nurse Learning Objectives
  • Recognize key elements of the ADA and AACE guidelines and identify new evidence of pharmacotherapies that pertain to non-glycemic outcomes
  • Recognize treatment options that optimize outcomes beyond A1c such as hypoglycemia, weight as well as cardiovascular and renal outcomes in patients with type 2 diabetes
  • Identify appropriate elements of an evidence-based treatment regimen that optimizes outcomes beyond hemoglobin A1c in patients with type 2 diabetes
 
Faculty
Dhiren PatelPharmD, CDE, BC-ADM, BCACP
Associate Professor of Pharmacy Practice, MCPHS University
 
ACPE UAN
0280-0000-18-082-L01-P (Knowledge-Based)
0280-0000-18-082-L01-T (Knowledge-Based)
0280-0000-18-082-L01-N (Knowledge-Based)
 
Credits
2
 
Handouts
 
Supported By
American Health Resources
 
As the nation’s opiate crisis continues, pharmacy personnel often find themselves thrust into a rapidly evolving regulatory theater as various agencies seek to reduce the impact of the current crisis in the United States.  This session seeks to identify the most common methods of diversion and to examine the “red flags” that pharmacy personnel should recognize as being potentially indicative of inappropriate access.  The concept of a pharmacist’s ‘corresponding responsibility’ will be carefully examined, including DEA expectations for recordkeeping upon facility audit.  The importance of proper drug disposal will be addressed within the context of preventing unintended diversion.
 
 
Pharmacist Learning Objectives
  • Recognize required recordkeeping regulations and expectations for a DEA pharmacy audit.
  • Recognize potential “red flags” as they relate to prescriptions and/or customers
  • List common drugs of abuse and methods of diversion.
  • Identify appropriate disposal options for controlled substances.
Pharmacy Technician Learning Objectives
  • Recognize required recordkeeping regulations and expectations for a DEA pharmacy audit.
  • Recognize potential “red flags” as they relate to prescriptions and/or customers
  • List common drugs of abuse and methods of diversion.
  • Identify appropriate disposal options for controlled substances.
Nurse Learning Objectives
  • Recognize required recordkeeping regulations and expectations for a DEA pharmacy audit.
  • Recognize potential “red flags” as they relate to prescriptions and/or customers
  • List common drugs of abuse and methods of diversion.
  • Identify appropriate disposal options for controlled substances.
 
Faculty
Claire BrennanDiversion Program Manager
Drug Enforcement Administration
 
ACPE UAN
0280-0000-18-097-L03-P (Knowledge-Based)
0280-0000-18-097-L03-T (Knowledge-Based)
0280-0000-18-097-L03-N (Knowledge-Based)
 
Credits
2
 
Handouts
 
Supported By
Drug Enforcement Administration
 
 
 
 
Requirements for CE Credit
  • Participant Requirement and Statement of Credit: To receive credit, participants must fully attend each session (no partial credit will be awarded), pass in a completed attendance verification form, and using the access code provided, complete the online evaluation for each session attended. Attendance will be verified. All participants will have the opportunity to evaluate the educational sessions and presenters as well as the ability to identify their
  • Pharmacists and Pharmacy Technicians: CE credit will be automatically uploaded to CPE Monitor upon completion of the evaluation and posted to the participant’s NABP account within 72 hours where an official certificate of credit can be printed. Evaluations must be completed within 60 days of program date to receive credit.
  • Statement of Disclosure: Disclosure will be made on the day of the program regarding any interest or affiliation a speaker may have with a supporting organization.
  • Refund Policy: A full refund will be provided only if a written request is received by American Health Resources, LLC at least 48 hours prior to the program or if the program is cancelled. American Health Resources, LLC reserves the right to change the presenters, topics or seminar schedules.
 
Only Certificates of Credit issued from CPE Monitor are valid in the US.
CPE Monitor will not accept credits after 60 days from the session date.
 
Supported By:
American Health Resources, LLC.
 
Registration closes on 11/28/2018 at 11:00 PM
 

CONTINUING EDUCATION

843 488 5550 Office

843 488 5554 Fax

info@ahrevents.com Email

www.ahrevents.com Web

341 Wellness Drive, Myrtle Beach, SC 29579 Address

©2015 PharmCon, lnc. All Rights Reserved | Terms & Conditions | Privacy PolicyAmerican Health Resources, LLC a subsidiary of PharmCon, Inc.
Developed By: ITB, Inc.